Pacira BioSciences Inc (NAS:PCRX)
$ 17.24 -0.46 (-2.6%) Market Cap: 796.03 Mil Enterprise Value: 986.64 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 71/100

Pacira Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:00PM GMT
Release Date Price: $36.82 (-0.70%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior Biotech Analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team. Our next presenting company is Pacira BioSciences. And speaking on behalf of the company, we have CEO, Dave Stack.

Before I turn it over to Dave, I just wanted to highlight to those listeners that we do have an Ask a Question button, where you could submit your question and I will try and get it in our discussion in 20 minutes or so here or you can raise your hand and ask it free form, so.

But with that, Dave, over to you.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Thank you, Tessa, and thanks to JPMorgan for having the opportunity to spend a few minutes with you folks today. So, Pacira is the leading company in non-opioid pain management and our mission is to provide an opioid alternative to as many patients as possible. To achieve that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot